Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Oculis Holding AG - Ordinary shares
(NQ:
OCS
)
10.98
+0.27 (+2.52%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,426,037
Open
10.97
Bid (Size)
10.54 (100)
Ask (Size)
10.98 (200)
Prev. Close
10.71
Today's Range
10.65 - 11.77
52wk Range
10.52 - 34.48
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS
Today 13:28 EDT
From
Pomerantz LLP
Via
GlobeNewswire
Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease
Today 4:00 EDT
From
Oculis Holding AG
Via
GlobeNewswire
Performance
YTD
-45.1%
-45.1%
1 Month
-66.4%
-66.4%
3 Month
-60.0%
-60.0%
6 Month
-46.7%
-46.7%
1 Year
-44.9%
-44.9%
More News
Read More
Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference
June 08, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles
↗
June 08, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Oculis Holding AG (NASDAQ:OCS) Q1 Earnings Miss Overshadowed by Key Pipeline Catalysts
↗
May 11, 2026
Via
Chartmill
Topics
Earnings
OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm
June 04, 2026
From
The Schall Law Firm
Via
Business Wire
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.
↗
June 03, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
OCS Investor Alert: Levi & Korsinsky Investigates Oculis Holding AG (OCS) for Potential Securities Fraud
June 03, 2026
From
Levi & Korsinsky, LLP
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS
June 02, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Which stocks are experiencing notable movement on Monday?
↗
June 01, 2026
Via
Chartmill
Which stocks are moving on Monday?
↗
June 01, 2026
Via
Chartmill
Monday's session: gap up and gap down stocks
↗
June 01, 2026
Via
Chartmill
Wondering what's happening in today's pre-market session?
↗
June 01, 2026
Via
Chartmill
Oculis Shelves FDA Filing After Phase 3 DME Trials Miss Key Vision Goals
↗
May 31, 2026
Via
MarketBeat
What's going on in today's after hours session
↗
May 29, 2026
Via
Chartmill
Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
May 29, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors
May 14, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Reports Q1 2026 Financial Results and Provides Company Update
May 11, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial
May 07, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting
May 05, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 01, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Publishes Invitation to the Annual General Meeting
April 21, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema
April 20, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis to Participate in Upcoming Investor Conferences
April 07, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
March 31, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Frequently Asked Questions
Is Oculis Holding AG - Ordinary shares publicly traded?
Yes, Oculis Holding AG - Ordinary shares is publicly traded.
What exchange does Oculis Holding AG - Ordinary shares trade on?
Oculis Holding AG - Ordinary shares trades on the Nasdaq Stock Market
What is the ticker symbol for Oculis Holding AG - Ordinary shares?
The ticker symbol for Oculis Holding AG - Ordinary shares is OCS on the Nasdaq Stock Market
What is the current price of Oculis Holding AG - Ordinary shares?
The current price of Oculis Holding AG - Ordinary shares is 10.98
When was Oculis Holding AG - Ordinary shares last traded?
The last trade of Oculis Holding AG - Ordinary shares was at 06/09/26 04:00 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.